Signal from the log
Specific Biologics
35 M$ · Series A · Canada · Biotech
Specific Biologics, à Toronto, développe Dualase, un outil d'édition du génome assez compact pour tenir dans un seul vecteur viral, qui raccourcit dans l'ADN des répétitions anormales. Son premier candidat vise la sclérose latérale amyotrophique liée au gène C9ORF72, pour laquelle aucun traitement n'est approuvé selon la société.
Article
Announced on , logged by the watch of 2 November 2026.
- Operation
- Funding round
- Announced amount
- 35 M$
- Stage
- Series A
- Country
- Canada
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by Hatteras Venture Partners , with Genesys Capital , BDC Life Sciences Venture Fund , DeepWork Capital , Seido Capital
Provenance
Source prnewswire
Logged on 2 November 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.